Genetron Holdings Announces Plan To Implement ADS Ratio Change From 1-5 To 1-15
-SEC Filing
-SEC Filing
Save time and jump to the most important pieces.
BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the "Merger") with Genetron New Co Limited ("Merger Sub"), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and wil
BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the "EGM") held today, the Company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Genetron New Co Limite
BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held at on February 21, 2024 at 9:00 a.m. (Beijing time) at 1/F, Building 11, Zone 1, No. 8 Life Science Parkway, Changping District, Beijing, People's Republic of China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and
BEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that the special committee (the "Special Committee") of the Company's Board of Directors (the "Board") has retained Kroll, LLC (operating through its Duff & Phelps Opinions Practice) as its independent financial advisor and Davis Polk & Wardwell LLP as its independent legal counsel. The Special Committee was formed to evaluate and consider the previously announced preliminary
--Closes $5 million Series A financing-- --Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations-- --Announces exclusive license of TellDx platform to Genetron Holdings Limited for China-- --Secures Deployment of TellDx at ARUP Laboratories, Inc-- BEVERLY, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection and treatment of cancer through its unique and proprietary circulating tumor cell (CTC) technology, TellDx, and complementary therapeutics platform, TellRx, today announced the closing of a $5 million Series A
BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Recorded total revenue of RMB 110.3 million (US $17.4 million) in the first quarter of 2022, representing 19.8% increase over the same period in 2021. LDT revenue was RMB 81.5 million (US $12.9 million), representing 13.5% increase over the same period in 2021.IVD re
BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open. Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, June 2, 2022. The conference call can be accessed by dialing the following numbers: United States:+1-833-239-5565China Domestic:400-820-528
BEIJING, March 29, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2021. 2021 and Recent Business Highlights Therapy Selection: As of December 31, 2021, the Company had 58 hospital partners, of which 30 were IVD hospital partners. Genetron Health is continuing to enhance its in-hospital sales effort.
15-12G - Genetron Holdings Ltd (0001782594) (Filer)
S-8 POS - Genetron Holdings Ltd (0001782594) (Filer)
25-NSE - Genetron Holdings Ltd (0001782594) (Subject)
SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)
SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)
SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)
Gainers OpGen, Inc. (NASDAQ:OPGN) jumped 593% to $2.33 following two SEC filings from the precision medicine company. The company has received an advanced payment of €750,000 related to the sale of certain Unyvero A50 systems by Curetis to a strategic partner. OpGen also announced a Preferred Stock Purchase Agreement. It signed an agreement with a certain investor to acquire 1,000 shares priced at $1,000 each, with gross proceeds of $1 million. Secoo Holding Limited (NASDAQ:SECO) shares climbed 577.7% to $2.17 after gaining around 12% on Wednesday. Versus Systems Inc. (NASDAQ:VS) shares jumped 305% to $0.8728 after gaining around 7% on Wednesday. Jaguar Health, Inc. (NASDAQ:JAGX) shar